

**CANM  
ACMN**

**Canadian Association of Nuclear  
Medicine**

**Association canadienne de  
médecine nucléaire**

*Final Program*

*Programme  
final*



*Photo credit: Tourism Calgary*

**CANM 2014 ANNUAL SCIENTIFIC  
MEETING**

**The Westin Calgary  
CALGARY, ALBERTA  
APRIL 10-13, 2014**

**RÉUNION ANNUELLE 2014  
DE L'ACMN**

**Le Westin Calgary  
CALGARY, (ALBERTA)  
Du 10 au 13 AVRIL 2014**

**2014 – CANM/ACMN  
ANNUAL SCIENTIFIC CONFERENCE / CONFÉRENCE SCIENTIFIQUE ANNUELLE**

**THURSDAY, April 10, 2014 / Le jeudi 10 avril 2014**

<b>1200 - 1300</b>	<b>CANM BOARD OF DIRECTORS LUNCH</b> (closed)- <i>Bonavista</i>
<b>1300 - 1700</b>	<b>CANM BOARD OF DIRECTORS MEETING</b> (closed)- <i>Bonavista</i>
<b>1500 - 1800</b>	<b>EXHIBITS AND POSTERS SET-UP</b> - <i>Foyer &amp; Mayfair/Endrooms</i>
<b>1800 - 1900</b>	<b>REGISTRATION and WELCOME RECEPTION with the Exhibitors</b> - <i>Foyer &amp; Mayfair/Endrooms</i>

**FRIDAY, April 11, 2014 / Le vendredi 11 avril 2014**

<b>0730 - 1730</b>	<b>REGISTRATION</b> - <i>Foyer</i>
<b>0730 - 1730</b>	<b>EXHIBITS OPEN</b> - <i>Foyer &amp; Mayfair/Endrooms</i>
<b>0730 - 0815</b>	<b>SUNRISE SYMPOSIUM with <i>continental breakfast</i></b> — <i>Britannia/Belaire</i> <b>Molecular Imaging &amp; Therapy of Prostate Cancer</b> <i>Chair: Norman Laurin</i> <i>Speaker: Christiaan Schiepers</i> <i>Objectives: Review and discuss NM imaging for prostate CA. Review available radiopharmaceuticals for imaging &amp; therapy. Preliminary results of treatment with Ra-223 radium di-chloride.</i>
<b>0815 - 0830</b>	<b>OPENING REMARKS</b> - <i>Britannia/Belaire</i>
<b>0830 - 1200</b>	<b>PLENARY 1 - Diagnosis and Treatment of Acute CAD</b> - <i>Britannia/Belaire</i> <i>Chair: Salem Yuoness /Lucille Lalonde</i> <b>0830-0900 Clinical Evaluation of Acute CAD</b> <i>Speaker: Lucille Lalonde</i> <i>Objectives: This presentation will review the clinical evaluation of acute coronary syndromes including acute MI (STEMI and NSTEMI), unstable angina and suspected unstable cardiac chest pain. At the end of this presentation the audience should be familiar with the data and tools used to reach a diagnosis and to achieve early risk stratification.</i> <b>0900-0920 Pathology of Acute CAD</b> <i>Speaker: Yinong Wang</i> <i>Objectives: Review the histopathology of acute CAD. Review current concepts of pathophysiology of acute CAD.</i> <b>0920-0950 Invasive Imaging of CAD</b> <i>Speaker: Angela Kealey</i> <i>Objectives: Understand the risks and benefits of invasive imaging in CAD. Understand the utility of intravascular ultrasound and hemodynamic assessment of coronary lesions. Understand the role of invasive imaging in acute and chronic CAD.</i> <b>0950-1020 CA Scoring &amp; CCTA In The Diagnosis of CAD</b> <i>Speaker: Carmen Lydell</i> <i>Objectives: To understand the techniques of coronary CTA and calcium scoring. To review the indications for coronary CTA and calcium scoring. To illustrate common scenarios for the utility of cardiac CTA and CA-scoring in Cardiology.</i> <b>1020-1040 REFRESHMENT BREAK</b> - <i>Foyer &amp; Mayfair/Endrooms</i> <b>1040-1120 Cardiac SPECT &amp; PET For The Diagnosis of CAD</b> <i>Speaker: David Wolinsky</i> <i>Objectives: Understand the role of Cardiac SPECT and PET in assessing diagnosis and prognosis in patients presenting with acute chest pain. Learn how to apply appropriate use of Criterion for SPECT and PET to chest pain and CAD scenarios. Appreciate the benefits of ischemic driven therapy based on SPECT and PET testing on outcomes in patients presenting with chest pain and acute CAD.</i> <b>1120-1200 Therapeutic Options in Acute CAD</b> <i>Speaker: Angela Kealey</i>

<b>1200 - 1300</b>	<b>LUNCHEON-</b> <i>Foyer &amp; Mayfair/Endrooms &amp; Britannia/Belaire</i>
<b>1300 - 1630</b>	<p><b>PLENARY 2 - Diagnosis and Treatment of Dementia-</b> <i>Britannia/Belaire</i>  <i>Chairs: Jean-Paul Soucy / Manish Joshi</i></p> <p><b>1300-1330 Clinical Evaluation</b>  Speaker: Eric Smith  <i>Objectives: To review common causes of dementia. To review diagnostic criteria for causes of dementia. To understand the role of clinical and cognitive testing in discriminating causes of dementia.</i></p> <p><b>1330-1400 CT, MRI</b>  Speaker: Manish Joshi  <i>Objectives: To understand the role of CT and MRI in the evaluation of dementia. To be aware of the CT and MRI appearances of common dementias. To understand the limitations of CT and MRI in the evaluation of dementia.</i></p> <p><b>1400-1430 Radiopharmaceuticals</b>  Speaker: Ingrid Koslowsky  <i>Objectives: To describe the mechanism of uptake of various brain imaging agents. To describe the radiopharmaceuticals currently being used for imaging AD. To describe the radiopharmaceuticals in development for imaging AD.</i></p> <p><b>1430-1500 REFRESHMENT BREAK-</b> <i>Foyer &amp; Mayfair/Endrooms</i></p> <p><b>1500-1530 SPECT, PET – Imaging of Dementia</b>  Speaker: Jean-Paul Soucy  <i>Objectives: Review current recommendations for Nuclear Medicine use in patients with cognitive disorders. Amyloid imaging and other future developments in Nuclear Medicine imaging of cognitive anomalies.</i></p> <p><b>1530-1600 Pathology of Dementia</b>  Speaker: Jeff Joseph  <i>Objectives: Present gross pathological changes of select diseases that correlate with neuroimaging. Demonstrate microscopic correlates of diminished brain activity. Show histology of select diseases, focusing on abnormal protein accumulation.</i></p> <p><b>1600-1630 Therapeutic Options</b>  Speaker: Eric Smith</p>
<b>1630 - 1730</b>	<p><b>AWARD and ABSTRACT PRESENTATIONS-</b> <i>Britannia/Belaire</i>  <i>Chair: Al Driedger / Denise Chan</i></p> <p><b>1630-1640 ERIC LEPP Competition Winner Presentation</b>  99m-Techneium-Labeled Heat-Damaged Red Blood Cell (RBC) Scintigraphy to Identify Intrahepatic Splenosis – <i>Alexander Tamm</i></p> <p><b>1640-1650</b> Patients with Somnambulism Show Specific Alterations in Brain Perfusion Patterns Following Sleep Deprivation -Abstract # 003 – <i>Jean-Paul Soucy</i></p> <p><b>1650-1700</b> Off-Label rhTSH Use for Preparation of Radioactive Iodine Treatment in Nodal Metastatic Thyroid Cancer is Safe &amp; Effective – Abstract #002- <i>Robert Wolfson</i></p> <p><b>1700-1710</b> Buccal Caffeine for the Reversal of Persantine Following Myocardial Perfusion Imaging – Abstract #006- <i>Murray Matangi</i></p> <p><b>1710-1730 POSTERS PRESENTATIONS</b></p>
<b>1730 - 1830</b>	<b>CANM AGM-</b> <i>Britannia/Belaire</i>
<b>1830 - ON</b>	<b>FREE EVENING</b>

## **SATURDAY, April 12, 2014 / Le samedi 12 avril 2014**

<b>0715 - 1630</b>	<b>REGISTRATION-</b> <i>Foyer</i>
<b>0715 - 0800</b>	<p><b>KEYNOTE LECTURE with <i>continental breakfast</i>-</b> <i>Britannia/Belaire</i>  <b>Molecular Imaging in Neuropsychiatry</b>  <i>Chair: Jean-Luc Urbain</i>  Speaker: Peter Herscovitch</p>

**0715 - 1700**

**EXHIBITS CONTINUE-***Foyer & Mayfair/Endrooms*

**0800 - 1300**

**CONCURRENT A – Part 1- Diagnosis and Treatment of Breast Cancer-** *Britannia/Belaire*

*Chairs: Denise Chan/B.J. Docktor*

**0800-0830 Clinical Perspectives**

Speaker: May Lynn Quan

*Objectives: To review the surgical management of breast cancer.*

**0830-0900 Mammography, US, MRI In Diagnosis and Follow-up**

Speaker: B. J. Docktor

**0900-0930 Scintimamamography and PET**

Speaker: Kathy Schilling

*Objectives: To discuss the use of nuclear imaging in the diagnosis of breast cancer diagnosis. To identify the differences between anatomic and functional breast imaging. To outline personalized surveillance plans for patients of variable risk level.*

**0930-1000 Pathology of Breast Cancer**

Speaker: Hua Yang

*Objectives: Current practice of breast pathology. Importance of clinical, radiological and pathological correlation in breast cancer diagnosis.*

**1000-1030 Surgical Options For Breast Cancer**

Speaker: May Lynn Quan

**1030-1100 Oncology Options For breast Cancer**

Speaker: Marc Webster

**1100-1130 REFRESHMENT BREAK-** *Foyer & Mayfair/Endrooms*

**CONCURRENT A- Part 2 – Sports Medicine-** *Britannia/Belaire*

*Chairs: Ho Jen*

**1130-1200 Clinical**

Speaker: Preston Wiley

*Objectives: To review common sporting bone injuries. To review treatment options for these injuries. To discuss imaging requirements for these injuries.*

**1200-1300 Bone SPECT/CT Imaging for MSK Injury: A Contemporary Approach**

Speaker: Ho Jen

*Objectives: Demonstrate the improved specificity in the diagnostic performance of modern bone scintigraphy by using detailed anatomy. Demonstrate how SPECT/CT imaging significantly improves diagnostic specificity over planar imaging. Review the role of bone scintigraphy with SPECT/CT imaging in the general context of musculoskeletal imaging: in relation to radiography, CT, ultrasound, MRI.*

**0800 - 1300**

**CONCURRENT B-Part 1- TECHNOLOGISTS' PROGRAM-** *Bonavista*

*Chairs: Kathryn Woodford & Angela Kaschel*

**0800-0830 Radioembolization of Hepatic Malignancies Using 90 Yttrium Microsphere Brachytherapy**

Speaker: Lawrence Lou

*Objectives: Radioembolization of Hepatic Malignancies using 90Yttrium Microsphere Brachytherapy. Understand the indication for Y-90 microsphere radioembolization. Understand patient screening and selection. Understand treatment planning for Y-90 microsphere radioembolization.*

**0830-0900 Brain Scintigraphy Seizures**

Speaker: Jeff Flemming

*Objectives: Review the technical factors related to acquiring SPECT images of the brain. Understand the utility of SPECT imaging in the management of seizures.*

**0900-0930 Gastric Emptying, Small and Large Bowel Transit**

Speaker: Jean-Luc Urbain

*Objectives: Review the anatomy of the GI tract. Review the fundamentals of GI tract physiology. Review the nuclear medicine procedures to evaluate the GI tract transit.*

**0930-1000 Making Cents Out of Seiverts**

Speaker: Betty Clarke

*Objectives: To simplify the significance of radiation exposure by converting Sieverts to dollars & cents.*

**1000-1030 Osteoporosis Canada Guidelines-What the Technologist Needs to Know**

Speaker: Jodie Piercey



*Objectives: Discuss the new 2010 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada and apply them in your daily practice to educate patients and other healthcare professionals. Discuss the prevalence and impact of osteoporosis in Canada. Explain the rationale for the development of Clinical Practice Guidelines and the major changes from the 2002 Guidelines. Briefly discuss the clinical tools used to assess a patient for osteoporosis. Discuss the indications for baseline bone density measurement. Explain the role of BMD in fracture risk assessment. Discuss how fracture risk assessment guides treatment and reassessment strategies.*

**1030-1100 Technical Aspects of Pediatric PET CT**

Speaker: Tina Alden

*Objectives: Describe the key elements required for successful pediatric FDG-PET/CT imaging. Compare pediatric and adult PET/CT imaging. Identify technical aspects important to F-DOPA.*

**1100-1130 REFRESHMENT BREAK-** Foyer & Mayfair/Endrooms

**CONCURRENT B-Part 2- TECHNOLOGISTS' PROGRAM-** Bonavista

Chair: Jodie Piercey

**1130-1200 Mo-99 Production**

Speaker: Doug Abrams

*Objectives: Overview of MO-99 production and distribution chain. MO99 capacity.*

**1200-1300 Cyclotron Produced Technetium**

Speaker: Katie Gagnon

**1100 - 1400 NM Specialty Committee Meeting (closed)-** Lake Louise

**1300 - 1400 LUNCHEON-** Foyer & Mayfair/Endrooms & Britannia/Belaire & Bonavista

**1400 - 1915 CONCURRENT C – Part 1- Nuclear Medicine in Musculoskeletal Infection-** Britannia/Belaire

Chairs: Reinhard Kloiber /Harvey Rabin

**1400-1415 Clinical**

Speaker: Harvey Rabin

**1415-1445 Radiologic Approaches**

Speaker: Kevin Tyler

*Objectives: To review the role of anatomic imaging in detecting sites of infection.*

**1445-1515 Radiopharmaceuticals**

Speaker: Ingrid Koslowsky

*Objectives: Discitis/Inflammation: To describe agents traditionally used for imaging inflammation. To list advantages of [18F] FDG in imaging discitis over traditional agents.*

**1515-1545 Nuclear Medicine and SPECT and PET-CT**

Speaker: Reinhard Kloiber

*Objectives: Review data on the utility of Nuclear Medicine procedures in diagnosis of spine infection. Review the utility of FDG PET/CT in musculoskeletal infection relative to other Nuclear Medicine techniques. Review appropriateness of various nuclear medicine techniques in specific categories of MSK infection including diagnostic utility, cost and patient acceptance.*

**1545-1600 Therapeutic Options**

Speaker: Harvey Rabin

**1600-1630 REFRESHMENT BREAK-** Foyer & Mayfair/Endrooms

**CONCURRENT C-Part 2 – Neuro-Endocrine Tumors-** Britannia/Belaire

Chairs: Sandy McEwan /Jean-Luc Urbain

**1630-1650 Patient Perspectives**

Speaker: Tisa Perra

*Objectives: Provide patient perspective (my personal story). Role of non-profits. CNETS Canada and Pheo Paratroopers – Introduce*

**1650-1720 The Surgeon Point of View**

Speaker: Janice Pasieka

*Objectives: Understand the surgical complexities of NET patients. Appreciate the role surgery plays in this disease. Importance of a multi-disciplinary approach.*

**1720-1740 Pathologist**

Speaker: Moosa Khalil

*Objectives: Pathologic classification of gastroenteropancreatic neuroendocrine tumors. Pathologic classification of pulmonary neuroendocrine tumors. Role of immunohistochemistry in the diagnosis and grading of neuroendocrine tumors.*

**1740-1810 The Oncologist Point of View**

Speaker: Dean Ruether

*Objectives: Outline the scope of the NET's. Present the case for multidisciplinary care of NET's. Update the status of system Rx options for NET's.*

**1810-1840 Radiopharmaceuticals**

Speaker: Pam Zabel

*Objectives: Describe radiopharmaceuticals commonly used in Diagnosis and Therapy of Neuroendocrine Cancer. Describe appropriate patient selection for Peptide Radionuclides Radiation Therapy (PRRT) via Multidisciplinary NET Team Case. Describe facilities, personnel, scheduling and radiation safety necessary for PRRT. Describe Patient infusion and follow-up.*

**1840-1915 Canadian Centre for Excellence**

Speaker: Sandy McEwan

*Objectives: Understand the role of multidisciplinary management in patients with neuroendocrine tumours. Understand the role of medical isotopes in this management. Understand the role importance of clinical trials to identify best management practices in the future.*

**1400 - 1800**

**CONCURRENT D – Part 1-TECHNOLOGISTS' PROGRAM- Bonavista**

*Chair: Jodie Piercey*

**1400-1430 Cardiac SPECT and PET/CT Update**

Speaker: Jonathan Abele

*Objectives: To review recent developments in cardiac SPECT and PET/CT. To describe the implementation of new MPI technologies in a major Canadian centre.*

**1430-1500 Approach to ECGs**

Speaker: Lucille Lalonde

*Objectives: This presentation will review the ECG changes that are relevant to the performance of cardiac nuclear imaging. This review will focus on rhythm, disturbances, and conduction abnormalities. At the end of this presentation, the audience should be familiar with the ECG findings that will influence the decision to proceed with cardiac nuclear imaging including contra-indications.*

**1500-1600 The Role of Nuclear Medicine in Cardiac Imaging**

Speaker: Emer Sonnex

*Objectives: Describe nuclear cardiac imaging. Reinforce when nuclear cardiac imaging is the modality of choice. What is new in cardiac nuclear imaging?*

**1600-1630 REFRESHMENT BREAK- Foyer & Mayfair/Endrooms**

**CONCURRENT D- Part 2-TECHNOLOGISTS' PROGRAM- Bonavista**

*Chair: Jodie Piercey*

**1630-1730 SPECT-CT Imaging for Sports Medicine**

Speaker: Ho Jen

**1730-1800 Kyphoplasty**

Speaker: Roy Park

*Objectives: To understand the indications for Kyphoplasty. To understand the treatment objectives of Kyphoplasty.*

**1930 - 2130**

**CANM ANNUAL DINNER & AWARDS- Bonavista**

**1930-2000 - Cocktails (cash bar) - Foyer**

**2000-2130 - Dinner**

**CANM Emeritus Award 2014 presented to Trevor Craddock**

**SUNDAY, April 13, 2014 / Le dimanche 13 avril 2014**

**0700 - 0800**

**REGISTRATION- Foyer**

**0700 - 0800**

**SUNRISE SYMPOSIUM with continental breakfast- Britannia/Belaire**

## **New American Thyroid Association (ATA) Guidelines on Thyroid Nodules and Differentiated Thyroid Cancers**

*Chair: Al Driedger*

*Speaker: Jennifer Sipos*

*Objectives: To review the recent changes in management of thyroid nodules. To discuss important changes in the treatment of differentiated thyroid cancer. To outline the recommended methods of long-term follow-up of patients with thyroid cancer.*

**0700 - 1030**

**EXHIBITS CONTINUE-** *Foyer & Mayfair/Endrooms*

**0800 - 1030**

### **PLENARY 3 – Head and Neck Cancers-** *Britannia/Belaire*

*Chairs: Jean-Luc Urbain / Harold Lau*

#### **0800-0830 Clinical Evaluation**

*Speaker: Harold Lau*

*Objectives: Review important clinical history and physical findings in the head and neck cancer patient.*

#### **0830-0900 Radiology/ Anatomy**

*Speaker: John Lysack*

*Objectives: Review the CT and MR imaging features of common head and neck cancers. Discuss the CT and MR imaging patterns of metastatic cervical lymphadenopathy. Emphasize the importance of clinical context in interpreting imaging findings.*

#### **0900-0930 FDG PET**

*Speaker: Jean-Luc Urbain*

*Objectives: Review the normal FDG PET findings for the head & neck. Review the lymph nodes levels of the neck. Understand the main FDG PET findings in ENT cancers.*

#### **0930-1000 Pathology**

*Speaker: Roderick Simpson*

#### **1000-1030 Treatment Options**

*Speaker: Harold Lau*

*Objectives: Overview of the major treatment options for common head and neck cancers.*

### **1030 - 1100 REFRESHMENT BREAK-** *Foyer & Mayfair/Endrooms*

**1100 - 1300**

### **PLENARY 4 – Update on Medical Isotopes-** *Britannia/Belaire*

*Chairs: Al Driedger / Ingrid Koslowsky*

#### **1100-1130 Reactors Production Of Moly-99 Across The World**

*Speaker: Doug Abrams*

#### **1130-1200 Tc-99m Production With Cyclotrons**

*Speaker: Katie Gagnon*

*Objectives: Introduce cyclotron production of 99mTc. Describe technical challenges/progress. Provide update on Canadian efforts and status.*

#### **1200-1230 Tc-99m Production with Linear Accelerators**

*Speaker: Kennedy Mang'era*

*Objectives: Introduce the technology and product evaluation principles. Present overview of research work. Review path and challenges to commercialization.*

#### **1230-1300 Emerging New Medical Isotopes**

*Speaker: Al Driedger*

*Objectives: Summarize historical approaches to nuclear-based therapies. Discuss prospects of newly introduced alpha emitters in therapy.*

**1300**

### **CLOSURE – END OF MEETING**

## **MAINTENANCE OF CERTIFICATION / MAINTIEN DU CERTIFICAT**

This event is an accredited group learning activity as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and pending approval by the Canadian Association of Nuclear Medicine.

*La présente activité, en demande d'approbation par l'Association canadienne de médecine nucléaire constitue une activité de formation collective agréée conformément à la définition précisée dans le programme de Maintien du certificat du Collège royal des médecins et chirurgiens du Canada.*

**2013 - 2014 CANM EXECUTIVE / CONSEIL DE L'ACMN 2013 -2014**

President, Norman Laurin  
President Elect/Vice-President, Andrew Ross  
Past President, Jean-Luc Urbain  
Secretary-Treasurer, Glenn Ollenberger  
Québec Representative, François Lamoureux  
Ontario Representative, Christopher O'Brien

Prairie Representative, Daniel Levin  
Western Representative, Phil Cohen  
Eastern Representative, Peter Hollett  
Foundation Chair, Al Driedger  
Education Committee Chair, Khun Visith Keu  
NM Specialty Committee Chair, David Barnes

### **SCIENTIFIC COMMITTEE - 2014 - *COMITÉ SCIENTIFIQUE***

Drs. Jean-Luc Urbain & Denise Chan, Chairs  
Ms. Jodie Piercey, *AB*  
Dr. Helen Nadel, *BC*  
Dr. Jonathan Abele, *AB*  
Dr. Reinhard Kloiber, *AB*

Dr. Doug Abrams, *AB*  
Dr. Christopher O'Brien, *ON*  
Dr. Khun Visith Keu, *Chair CPD Committee, QC*  
Dr. Salem Yuoness, *ON*

### **VISIT OUR WEBSITE / *VISITEZ NOTRE SITE WEB***

For information, please visit our Website at:  
Pour de plus amples informations, veuillez consulter notre site web :

[www.canm-acmn.ca](http://www.canm-acmn.ca)

*To contact us / Pour nous rejoindre:*  
*P.O. Box 4383, Station 'E'*  
*Ottawa, ON K1S 2L0*  
*Tel: 613-882-5097*  
*Email / Courriel : [canm@canm-acmn.ca](mailto:canm@canm-acmn.ca)*



**The Canadian Association of Nuclear Medicine  
gratefully acknowledges  
educational support from the following sponsors:**

***L'Association canadienne de médecine nucléaire  
remercie sincèrement les commanditaires suivants  
pour leur soutien didactique:***

## **GOLD**



## **SILVER**

GE Healthcare



**PHILIPS**

**SIEMENS**

## **BRONZE PLUS**



## **BRONZE**



**Bayer**



**CardinalHealth**  
Essential to care™

**cyclomedica**

